Shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) traded up 4.6% during trading on Friday . The stock traded as high as $3.63 and last traded at $3.62, with a volume of 951,499 shares. The stock had previously closed at $3.46.

Several analysts recently commented on the company. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, May 9th. Jefferies Group raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, June 1st. Finally, FBR & Co reaffirmed a “buy” rating and issued a $6.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, July 6th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. BioCryst Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $9.70.

The company’s 50-day moving average is $2.98 and its 200 day moving average is $3.42. The firm’s market cap is $266.77 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.08. The firm had revenue of $4.82 million for the quarter, compared to analyst estimates of $5.42 million. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. The firm’s quarterly revenue was down 29.4% on a year-over-year basis. Analysts predict that BioCryst Pharmaceuticals Inc. will post ($1.06) EPS for the current fiscal year.

Other large investors have recently bought and sold shares of the company. Morgan Stanley raised its stake in BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 12,646 shares during the last quarter. Globeflex Capital L P purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at about $1,241,000. Finally, Jennison Associates LLC raised its stake in BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock valued at $13,917,000 after buying an additional 24,014 shares during the last quarter.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.